319 related articles for article (PubMed ID: 35460465)
21. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
Brunet S; Martino R; Sierra J
Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
[TBL] [Abstract][Full Text] [Related]
22. TKI Maintenance After Stem-Cell Transplantation for
Gagelmann N; Wolschke C; Klyuchnikov E; Christopeit M; Ayuk F; Kröger N
Front Immunol; 2021; 12():630429. PubMed ID: 33790903
[TBL] [Abstract][Full Text] [Related]
23. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
24. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR; Baumgartner F; Braun L; O'Sullivan D; Thomas S; Waterhouse M; Müller TA; Hanke K; Taromi S; Apostolova P; Illert AL; Melchinger W; Duquesne S; Schmitt-Graeff A; Osswald L; Yan KL; Weber A; Tugues S; Spath S; Pfeifer D; Follo M; Claus R; Lübbert M; Rummelt C; Bertz H; Wäsch R; Haag J; Schmidts A; Schultheiss M; Bettinger D; Thimme R; Ullrich E; Tanriver Y; Vuong GL; Arnold R; Hemmati P; Wolf D; Ditschkowski M; Jilg C; Wilhelm K; Leiber C; Gerull S; Halter J; Lengerke C; Pabst T; Schroeder T; Kobbe G; Rösler W; Doostkam S; Meckel S; Stabla K; Metzelder SK; Halbach S; Brummer T; Hu Z; Dengjel J; Hackanson B; Schmid C; Holtick U; Scheid C; Spyridonidis A; Stölzel F; Ordemann R; Müller LP; Sicre-de-Fontbrune F; Ihorst G; Kuball J; Ehlert JE; Feger D; Wagner EM; Cahn JY; Schnell J; Kuchenbauer F; Bunjes D; Chakraverty R; Richardson S; Gill S; Kröger N; Ayuk F; Vago L; Ciceri F; Müller AM; Kondo T; Teshima T; Klaeger S; Kuster B; Kim DDH; Weisdorf D; van der Velden W; Dörfel D; Bethge W; Hilgendorf I; Hochhaus A; Andrieux G; Börries M; Busch H; Magenau J; Reddy P; Labopin M; Antin JH; Henden AS; Hill GR; Kennedy GA; Bar M; Sarma A; McLornan D; Mufti G; Oran B; Rezvani K; Shah O; Negrin RS; Nagler A; Prinz M; Burchert A; Neubauer A; Beelen D; Mackensen A; von Bubnoff N; Herr W; Becher B; Socié G; Caligiuri MA; Ruggiero E; Bonini C; Häcker G; Duyster J; Finke J; Pearce E; Blazar BR; Zeiser R
Nat Med; 2018 Mar; 24(3):282-291. PubMed ID: 29431743
[TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy for
Burchert A
Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354
[TBL] [Abstract][Full Text] [Related]
28. [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Zu YL; Zhang YL; Zhou J; Han LJ; Zhao HF; Gui RR; Hou YJ; Song YP
Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):634-6. PubMed ID: 27480560
[TBL] [Abstract][Full Text] [Related]
29. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
31. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
32. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of FLT3 in AML: a focus on sorafenib.
Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
[TBL] [Abstract][Full Text] [Related]
35. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia.
Hilger N; Mueller C; Stahl L; Mueller AM; Zoennchen B; Dluczek S; Halbich C; Wickenhauser C; Gerloff D; Wurm AA; Behre G; Kretschmer A; Fricke S
Front Immunol; 2018; 9():2408. PubMed ID: 30405611
[TBL] [Abstract][Full Text] [Related]
36. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
[TBL] [Abstract][Full Text] [Related]
37. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
38. The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
Qiu QC; Wang C; Bao XB; Yang J; Shen HJ; Ding ZX; Liu H; He J; Yao H; Chen SN; Li Z; Xue SL; Liu SB
Hematology; 2018 Apr; 23(3):131-138. PubMed ID: 28876197
[TBL] [Abstract][Full Text] [Related]
39. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
40. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y
Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
